New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated ...

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI ...

A senior senator has asked the CEOs of both companies to provide information about the limits they are putting on 340B drug ...

Regulators, policymakers and others can more effectively battle the disease by creating incentives to make mpox a more ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Flagship Pioneering–backed Generate:Biomedicines has signed its second major Big Pharma partnership, bringing in $65 million upfront to use its AI platform to discover novel protein drug candidates.

Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s ...